Literature DB >> 19033674

Real-time assessment of inflammation and treatment response in a mouse model of allergic airway inflammation.

Virna Cortez-Retamozo1, Filip K Swirski, Peter Waterman, Hushan Yuan, Jose Luiz Figueiredo, Andita P Newton, Rabi Upadhyay, Claudio Vinegoni, Rainer Kohler, Joseph Blois, Adam Smith, Matthias Nahrendorf, Lee Josephson, Ralph Weissleder, Mikael J Pittet.   

Abstract

Eosinophils are multifunctional leukocytes that degrade and remodel tissue extracellular matrix through production of proteolytic enzymes, release of proinflammatory factors to initiate and propagate inflammatory responses, and direct activation of mucus secretion and smooth muscle cell constriction. Thus, eosinophils are central effector cells during allergic airway inflammation and an important clinical therapeutic target. Here we describe the use of an injectable MMP-targeted optical sensor that specifically and quantitatively resolves eosinophil activity in the lungs of mice with experimental allergic airway inflammation. Through the use of real-time molecular imaging methods, we report the visualization of eosinophil responses in vivo and at different scales. Eosinophil responses were seen at single-cell resolution in conducting airways using near-infrared fluorescence fiberoptic bronchoscopy, in lung parenchyma using intravital microscopy, and in the whole body using fluorescence-mediated molecular tomography. Using these real-time imaging methods, we confirmed the immunosuppressive effects of the glucocorticoid drug dexamethasone in the mouse model of allergic airway inflammation and identified a viridin-derived prodrug that potently inhibited the accumulation and enzyme activity of eosinophils in the lungs. The combination of sensitive enzyme-targeted sensors with noninvasive molecular imaging approaches permitted evaluation of airway inflammation severity and was used as a model to rapidly screen for new drug effects. Both fluorescence-mediated tomography and fiberoptic bronchoscopy techniques have the potential to be translated into the clinic.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19033674      PMCID: PMC2579705          DOI: 10.1172/JCI36335

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  62 in total

1.  Serum concentration and circadian profiles of cathepsins B, H and L, and their inhibitors, stefins A and B, in asthma.

Authors:  N Cimerman; P Mesko Brguljan; M Krasovec; S Suskovic; J Kos
Journal:  Clin Chim Acta       Date:  2001-08-20       Impact factor: 3.786

2.  In vivo molecular target assessment of matrix metalloproteinase inhibition.

Authors:  C Bremer; C H Tung; R Weissleder
Journal:  Nat Med       Date:  2001-06       Impact factor: 53.440

3.  Fluorescence molecular tomography resolves protease activity in vivo.

Authors:  Vasilis Ntziachristos; Ching-Hsuan Tung; Christoph Bremer; Ralph Weissleder
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

4.  Imaging the lungs in asthmatic patients by using hyperpolarized helium-3 magnetic resonance: assessment of response to methacholine and exercise challenge.

Authors:  Saba Samee; Talissa Altes; Patrick Powers; Eduard E de Lange; Jack Knight-Scott; Gary Rakes; John P Mugler; Jonathan M Ciambotti; Bennet A Alford; James R Brookeman; Thomas A E Platts-Mills
Journal:  J Allergy Clin Immunol       Date:  2003-06       Impact factor: 10.793

Review 5.  Matrix metalloproteinases as modulators of inflammation and innate immunity.

Authors:  William C Parks; Carole L Wilson; Yolanda S López-Boado
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

Review 6.  Role of matrix metalloproteinases in asthma.

Authors:  Elizabeth A Kelly; Nizar N Jarjour
Journal:  Curr Opin Pulm Med       Date:  2003-01       Impact factor: 3.155

7.  Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation.

Authors:  Didier D Cataldo; Kurt G Tournoy; Karim Vermaelen; Carine Munaut; Jean-Michel Foidart; Renaud Louis; Agnès Noël; Romain A Pauwels
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

8.  Interleukin-13-dependent expression of matrix metalloproteinase-12 is required for the development of airway eosinophilia in mice.

Authors:  Mahmoud A Pouladi; Clinton S Robbins; Filip K Swirski; Meghan Cundall; Andrew N J McKenzie; Manel Jordana; Steven D Shapiro; Martin R Stämpfli
Journal:  Am J Respir Cell Mol Biol       Date:  2003-07-03       Impact factor: 6.914

Review 9.  Pathogenic role of matrix metalloproteases and their inhibitors in asthma and chronic obstructive pulmonary disease and therapeutic relevance of matrix metalloproteases inhibitors.

Authors:  D D Cataldo; M M Gueders; N Rocks; N E Sounni; B Evrard; P Bartsch; R Louis; A Noel; J M Foidart
Journal:  Cell Mol Biol (Noisy-le-grand)       Date:  2003-09       Impact factor: 1.770

10.  Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling.

Authors:  Sophie Lanone; Tao Zheng; Zhou Zhu; Wei Liu; Chun Geun Lee; Bing Ma; Qingsheng Chen; Robert J Homer; Jingming Wang; Lesley A Rabach; Morgan E Rabach; J Michael Shipley; Steven D Shapiro; Robert M Senior; Jack A Elias
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

View more
  42 in total

1.  Imaging of molecular signatures of specific structures, functions,and pathological alterations in the lung tissue.Chair's Summary.

Authors:  Vladimir R Muzykantov
Journal:  Proc Am Thorac Soc       Date:  2009-08-15

2.  Micro-endoscopy for Live Small Animal Fluorescent Imaging.

Authors:  Bjorn Paulson; Jun Ki Kim
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Paradigms in Fluorescence Molecular Imaging: Maximizing Measurement of Biological Changes in Disease, Therapeutic Efficacy, and Toxicology/Safety.

Authors:  Jeffrey D Peterson
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

4.  Detection and monitoring of localized matrix metalloproteinase upregulation in a murine model of asthma.

Authors:  Csilla N Felsen; Elamprakash N Savariar; Michael Whitney; Roger Y Tsien
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-02-07       Impact factor: 5.464

5.  Imaging of molecular probe activity with Born-normalized fluorescence optical projection tomography.

Authors:  Claudio Vinegoni; Paolo Fumene Feruglio; Virna Cortez-Retamozo; Daniel Razansky; Benjamin D Medoff; Vasilis Ntziachristos; Andrea Sbarbati; Mikael Pittet; Ralph Weissleder
Journal:  Opt Lett       Date:  2010-04-01       Impact factor: 3.776

6.  Biochemical characterization of a Caspase-3 far-red fluorescent probe for non-invasive optical imaging of neuronal apoptosis.

Authors:  Valérie Jolivel; Sébastien Arthaud; Béatrice Botia; Christophe Portal; Bruno Delest; Guillaume Clavé; Jérôme Leprince; Anthony Romieu; Pierre-Yves Renard; Omar Touzani; Heidi Ligeret; Pauline Noack; Marc Massonneau; Alain Fournier; Hubert Vaudry; David Vaudry
Journal:  J Mol Neurosci       Date:  2014-05-28       Impact factor: 3.444

7.  Non-invasive In Vivo Fluorescence Optical Imaging of Inflammatory MMP Activity Using an Activatable Fluorescent Imaging Agent.

Authors:  Johannes Schwenck; Florian C Maier; Manfred Kneilling; Stefan Wiehr; Kerstin Fuchs
Journal:  J Vis Exp       Date:  2017-05-08       Impact factor: 1.355

8.  A wortmannin-cetuximab as a double drug.

Authors:  R Adam Smith; Hushan Yuan; Ralph Weissleder; Lewis C Cantley; Lee Josephson
Journal:  Bioconjug Chem       Date:  2009-11       Impact factor: 4.774

9.  Noninvasive monitoring of pulmonary fibrosis by targeting matrix metalloproteinases (MMPs).

Authors:  Yan Cai; Lei Zhu; Fan Zhang; Gang Niu; Seulki Lee; Shioko Kimura; Xiaoyuan Chen
Journal:  Mol Pharm       Date:  2013-05-08       Impact factor: 4.939

10.  Multicolor fluorescent intravital live microscopy (FILM) for surgical tumor resection in a mouse xenograft model.

Authors:  Greg M Thurber; Jose L Figueiredo; Ralph Weissleder
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.